Ernexa Therapeutics Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Ernexa Therapeutics Inc. (ERNA) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 497 shares for the 3-month period ending 2012-09-30, per its 10-Q filed 2013-11-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2013-11-14
- Ernexa Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2012-09-30 was 497.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month |
|---|---|
| 2012-09-30 | 497.00 shares 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |